Turn Therapeutics — Third Quarter 2026 Earnings Summary

Turn Therapeutics reported that 59.3% of patients in its completed Stage 1/Phase 2a trial for GX-03 achieved clear or almost clear skin after four weeks, compared to 30.4% in the vehicle group. The company is accelerating enrollment for a Phase 2a trial of GX-03 in hidradenitis suppurativa, now expected to begin in the first quarter of 2027, while a larger Phase 2b trial for atopic dermatitis continues with no patient dropouts. Robert R. Redfield, former CDC Director, has been appointed as Chief Scientific Officer to guide the company's clinical strategy. Financially, the company held $10.4 million in cash as of September 30, 2026, which is projected to fund operations into the third quarter of 2027.